Baudax Bio, Inc., a pharmaceutical company specializing in acute care therapies, announced that ANJESO (meloxicam), the only 24-hour intravenous COX-2 preferred nonsteroidal anti-inflammatory drug , is now available at command. and deliver goods to customers. ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020, and is indicated for the treatment of moderate to severe pain, alone or in combination with other medications. Other non-NSAID pain relievers.
Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important needs of patients, today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults to soft tissue or periarticular drops to provide postoperative analgesia for up to 72 hours after bunionectomy, open inguinal hernia, and total knee replacement surgery.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5360
Published Date: Nov 02, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of chronic pain disease and increasing research and development in meloxicam are some of the major factors anticipated to drive the growth of the meloxicam market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.
The major players in the market are of Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc., and others.
The osteoarthritis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.